Northwest Biotherapeutics (LTS:0K95) Operating Cash Flow per Share : £-0.04 (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Northwest Biotherapeutics Operating Cash Flow per Share?

Northwest Biotherapeutics's operating cash flow per share for the three months ended in Mar. 2024 was £-0.01. Northwest Biotherapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was £-0.04.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -2.90% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 7.90% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 32.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Northwest Biotherapeutics's Operating Cash Flow per Share or its related term are showing as below:

LTS:0K95' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -7.4 Med: 33.6 Max: 63.1
Current: -2.9

During the past 13 years, Northwest Biotherapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 63.10% per year. The lowest was -7.40% per year. And the median was 33.60% per year.

LTS:0K95's 3-Year OCF Growth Rate is ranked worse than
58.3% of 1235 companies
in the Biotechnology industry
Industry Median: 3.4 vs LTS:0K95: -2.90

Northwest Biotherapeutics Operating Cash Flow per Share Historical Data

The historical data trend for Northwest Biotherapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Northwest Biotherapeutics Operating Cash Flow per Share Chart

Northwest Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-0.04

-0.03

-0.04

Northwest Biotherapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.01	-0.01	-0.01	-0.01	-0.01

Competitive Comparison of Northwest Biotherapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, Northwest Biotherapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Northwest Biotherapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Northwest Biotherapeutics's Price-to-Operating-Cash-Flow falls into.

Northwest Biotherapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Northwest Biotherapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-42.373	/	1119.191
	=	-0.04

Northwest Biotherapeutics's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )	=	Cash Flow from Operations (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	-9.764	/	1188.149
	=	-0.01

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was £-0.04

Northwest Biotherapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Northwest Biotherapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Northwest Biotherapeutics (LTS:0K95) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (LTS:0K95) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

NWBO:USA NBYB:Germany

Address

4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814

Website

https://www.nwbio.com

Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.

Northwest Biotherapeutics (LTS:0K95) Headlines

No Headlines